Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > ot) Awaiting 5 FDA approvals (Mcap 57 M)
View:
Post by BionicheStar on Jul 29, 2011 8:50am

ot) Awaiting 5 FDA approvals (Mcap 57 M)

GET IN NOW BEFORE THE STOCK GETS DISCOVERED !!!

This Unknown ULTRA LOW FLOAT Stock awaiting 5 FDA approvals and willrise to 7 by year end .I.TO has 15 Drugs in Pipeline many nearingANDA/NDA filing including a potential Blockbuster .

Market Cap 57 Mil / Cash 8.5 M / Burn-rate 4.5 M per Year = Enough Cash until Profitability which will happen in 2012

First FDA approval and PartnerShip which is imminent will push this low float rocket into double digits easily ..GLTA


Intellipharmaceutics (I.TO)

Market Cap: 57 M
Cash: 8.5 M
Price: 3.60 $

Shares Out: 15.9 Mil..(13 Mil Shares held by Insiders/Institutions)
Low Float : 2 M


Intellipharmaceutics now has five ANDAs awaiting FDA approval withreported sales for branded and generic versions of these products beingapproximately $8 billion in 2010. The Company develops both ANDA productcandidates and new drugs through the New Drug Application (NDA)505(b)(2) regulatory pathway.


"The filing of a generic version of Seroquel XR® is one of the Company'sperformance milestones for 2011 and another important addition to ourproduct portfolio filed for approval with the FDA, which includesgenerics of Focalin XR®, Effexor XR®, Protonix® DR and Glucophage® XR,"commented Dr. Isa Odidi, CEO of Intellipharmaceutics. "These filings notonly provide further validation of our Hypermatrix™ technology, theyclearly demonstrate the flexibility of our technology to efficiently andeffectively match a number of drug delivery profiles."
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities